Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan
Authors' conclusion
With the introduction of new treatments and emerging evidence supporting cardio-renal protective effects in people with CKD and T2D, notable changes in baseline treatment were observed in the medication-initiator cohort characteristics. These findings suggest the earlier use of cardio-renal protective medications in the course of T2D.
Study context
- Population
- Adults with Chronic Kidney Disease (CKD) and T2D initiating SGLT2i or GLP-1 RA, Japan Chronic Kidney Disease Database Extension
- Participants
- 1,157 / 1,122 / 329 / 369
- Exposure
- Medication-initiator cohort characteristics, Period I vs Period II, for SGLT2i and GLP-1 RA initiators
- SGLT-2i Period In = 1,157reference
- SGLT-2i Period IIn = 1,122
- GLP-1RA Period In = 329reference
- GLP-1RA Period IIn = 369
- Outcome
- Baseline characteristics and SMD between periods I and II
Methodological detailsnew-user cohorts, two study periods
- New-user cohorts
- Two study periods
Main finding
As reported in the abstract
Baseline characteristics, Period I vs II
- All four cohorts had similar age, sex and comorbidity patterns; mean age
- 66.1-69.5 years
- Male
- 60%-70%
- Hypertension
- More than 80%
- Congestive HF
- 60%
- SGLT2i cohorts: decrease in prior metformin and DPP-4i use
- SMD ≥0.5 and <0.8
- SGLT2i cohorts: increase in persons with no T2D medications other than insulin
- SMD >0.8
Observational data: associations, not effects.
Original publication
Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan. Diabetes Obes Metab. Published 21 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →